Literature DB >> 26315482

Risk factors for in-hospital mortality in patients with type 2 diabetes complicated by community-acquired Klebsiella pneumoniae bacteremia.

Chung-Huei Huang1, Jir-Shiong Tsai2, I-Wen Chen1, Brend Ray-Sea Hsu1, Miau-Ju Huang1, Yu-Yao Huang3.   

Abstract

BACKGROUND/
PURPOSE: Patients with diabetes are at a high risk of infection-related morbidity and mortality. Klebsiella pneumoniae bacilli are prevalent among diabetic patients, especially in Asian populations. The present study aimed to identify risk factors for in-hospital mortality among diabetic patients complicated by community-acquired K. pneumoniae bacteremia.
METHODS: We evaluated the clinical characteristics of 341 Taiwanese type 2 diabetic patients who were treated for community-acquired K. pneumoniae bacteremia. We then analyzed outcome predictors, and in particular comorbidities and the site of infection.
RESULTS: The overall in-hospital mortality rate was 14.1%. Comorbid cancer was the leading factor, accounting for 32.1% of all cases of mortality. Pulmonary infection, primary bacteremia, afebrile or shock presentation and low serum albumin level were risk factors for in-hospital mortality. Regardless of comorbidities, pulmonary infection [odds ratio (OR) 10.74, 95% confidence interval (CI) 2.02-57.09] and albumin level (OR 0.15, 95% CI 0.03-0.76) were the main risk predictors. The receiver operating characteristic curve indicated that a serum albumin level lower than 2.4 g/dL (71.1% sensitivity and 77.4% specificity) suggested a poor prognosis in the diabetic patients with K. pneumoniae bacteremia. In patients with pulmonary infection, the capsular serotypes of K. pneumoniae were not related to poor outcomes, and an initial presentation of blunted fever or shock were independent factors for mortality.
CONCLUSION: Cancer, pulmonary infection, and low serum albumin levels were independent indicators of in-hospital mortality in the diabetic patients complicated by K. pneumoniae bacteremia. The sites of infection and host characteristics should always elicit medical attention when treating these patients.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Klebsiella pneumonia; albumin; community-acquired bacteremia; sites of infection; type 2 diabetes mellitus

Mesh:

Substances:

Year:  2015        PMID: 26315482     DOI: 10.1016/j.jfma.2015.07.011

Source DB:  PubMed          Journal:  J Formos Med Assoc        ISSN: 0929-6646            Impact factor:   3.282


  5 in total

1.  Synthesis and biological evaluation of indole core-based derivatives with potent antibacterial activity against resistant bacterial pathogens.

Authors:  Wei Hong; Jingyang Li; Zhe Chang; Xiaoli Tan; Hao Yang; Yifan Ouyang; Yanhui Yang; Sargit Kaur; Ian C Paterson; Yun Fong Ngeow; Hao Wang
Journal:  J Antibiot (Tokyo)       Date:  2017-05-03       Impact factor: 2.649

2.  Age, Pulse, Urea and Albumin (APUA) Model: A Tool for Predicting in-Hospital Mortality of Community-Acquired Pneumonia Adapted for Patients with Type 2 Diabetes.

Authors:  Chun-Ming Ma; Ning Wang; Quan-Wei Su; Ying Yan; Fu-Zai Yin
Journal:  Diabetes Metab Syndr Obes       Date:  2020-10-09       Impact factor: 3.168

3.  Occurrence and determinants of Klebsiella species bloodstream infection in the western interior of British Columbia, Canada.

Authors:  Connor B Reid; Lisa Steele; Kelsey Pasquill; Elizabeth C Parfitt; Kevin B Laupland
Journal:  BMC Infect Dis       Date:  2019-12-19       Impact factor: 3.090

4.  Impact of wound microbiology on limb preservation in patients with diabetic foot infection.

Authors:  Shih-Yuan Hung; Cheng-Hsun Chiu; Chung-Huei Huang; Cheng-Wei Lin; Jiun-Ting Yeh; Hui-Mei Yang; Yu-Yao Huang
Journal:  J Diabetes Investig       Date:  2021-09-08       Impact factor: 4.232

Review 5.  Elevated Mortality Risk from CRKp Associated with Comorbidities: Systematic Review and Meta-Analysis.

Authors:  Lucas Candido Gonçalves Barbosa; José Arthur Silva E Sousa; Graziela Picciola Bordoni; Gabriel de Oliveira Barbosa; Lilian Carla Carneiro
Journal:  Antibiotics (Basel)       Date:  2022-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.